LSUHSC Minority Based Community Clinical Oncology

路易斯安那州立大学是1994年至2000年资助的少数族裔社区临床肿瘤学项目(MB CCOP)。去年提交的申请得到了好评，但没有获得资金。这份申请书是一份修改后的申请书，它解决了去年提交的总结声明中提出的问题，对我们之前对计划的描述进行了扩展，并更新了我们的当前状态。这项提案表明，我们继续致力于在路易斯安那州南部少数族裔和服务不足的人群中控制癌症。根据路易斯安那州的癌症发病率，癌症死亡率高于预期。这在一定程度上是由于诊断处于晚期，在服务不足和少数群体中似乎更严重。贫困人口可以通过全州范围的医院系统获得护理，因此障碍可能更多的是信息方面的，而不是物质上的或经济上的。我们需要的是外展，这是我们的优势。尽管我们在治疗方面的努力是成功的，但我们在少数族裔登记参加癌症预防研究的结果以及产生这些登记的外展努力将对癌症控制产生更大的影响。在STAR计划的第一年，我们招收了19%的少数族裔女性，这大约是全国研究的十倍。在此之前，我们在PCPT取得了类似的成功，在那里，我们的少数族裔入学率是全国研究的四倍。当SELECT在9月份开放时，我们相信我们已经建立的外展努力将导致大量非裔美国人加入这项研究。我们扭转了治疗和癌症控制登记人数的下降趋势，并通过以下目标建议继续取得成功：(1)继续与我们的精干数据管理团队协作，(2)增加对STAR和ADD SELECT项目的参与，(3)继续只开放那些有可能实现收益的研究，(4)增加医生对支持MB CCOP试验的激励，(5)仔细权衡扩大规模的机会，以继续专注于我们针对路易斯安那州少数族裔和服务不足人群的外联目标。国家癌症研究所的财政支持将确保我们继续取得成功。

LSU was a funded Minority-Based Community Clinical Oncology Program (MB CCOP) from 1994 to 2000. Last year's submission received a favorable review but not funding. This submission is an amended application which addresses the points raised in the Summary Statement of last years submission, expands on previous descriptions of our program, and updates our current status. The proposal demonstrates our continued commitment to efforts to cancer control in the minority and under-served populations of southern Louisiana. Cancer mortality is greater than expected based on cancer incidence in Louisiana. This, in part, is due to advanced stage at diagnosis which appears to be greater among underserved and minority population. Access to care is available through a statewide hospital system for indigent populations so the barriers may be more informational than physical or financial. Outreach is what is needed and that is our strength. Although we are successful in treatment efforts, our results in minority enrollment onto cancer prevention studies and the outreach efforts which produces those enrollments will have a greater impact in cancer control. During our first year of the STAR program we enrolled 19% minority women which was roughly ten times that of the national study. This follows a similar success we enjoyed with PCPT where we had four times higher minority enrollment percentage than did the national study. When SELECT opens in September, we are confident the outreach efforts we have established will result in large numbers of African-American men joining the study. We have reversed declines in treatment and cancer control enrollments and propose continued success via the following goals: (1) Continue the collaborative efforts of our capable data management team, (2) Increase participation in STAR and add SELECT, (3) Continue to open only those studies likely to achieve accrual, (4) Increase physician incentives for support of the MB CCOP trials, (5) Carefully weigh expansion opportunities to remain focused on our goal of outreach to minority and under-served populations of Louisiana. The financial support of the National Cancer Institute will assure our continued success.